- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05310955
Intervention Effect of Shen-based Qigong Exercise on Residual Symptoms of Schizophrenia
October 25, 2022 updated by: Shanghai Mental Health Center
Discussion on the Intervention Effect of Shen-based Qigong Exercise on Residual Symptoms of Schizophrenia Based on the Theory of "Heart Dominating Mind" and "Body-spirit Syncretism" in Traditional Chinese Medicine
The purpose of this study is to observe the intervention effect of shen-based Qigong exercise on residual symptoms of schizophrenia.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Shen-based Qigong exercise is a new kind of health-care Qigong exercise based on the theory of traditional Chinese medicine, aiming at the characteristics of schizophrenia.
In this study, a randomized controlled trial was conducted to observe the rehabilitation effect of this new exercise on residual symptoms of schizophrenic patients.
Questionnaire, test and other experimental materials were used to evaluate the intervention effect of 12-week shen-based Qigong exercise on psychiatric symptoms, cognitive function, quality of life and social function of schizophrenic patients.
At the same time, the related physical function and cardiac function indexes were used to evaluate the physical and cardiac rehabilitation effects of the exercise on patients from the aspects of "body" and "heart", so as to verify whether Qigong exercise has the effects of adjusting body and heart.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anbei Lian
- Phone Number: 18117205070
- Email: 782115188@qq.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Mental Health Center
-
Contact:
- Anbei Lian
- Phone Number: 18117205070
- Email: 782115188@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Han Chinese population
- age ≥ 18 years
- education level ≥ 6 years, can fill in the questionnaire independently, have enough audio-visual level to complete the necessary examination
- assessed by MINI 7.0 and satisfied with the diagnostic criteria for schizophrenia based on the Diagnostic and Statistical Manual of Mental Disorders, fifth edition(DSM-5)
- patients with schizophrenia residing in the rehabilitation ward, without relapse in the past 6 months
- residual negative symptoms, with at least one item ≥ 2 on the negative subscale of PANSS (N1-N7)
- taking second generation antipsychotics
- no training history of traditional Chinese exercises
- agreement to participate in the study and willing to give written informed consent
Exclusion Criteria:
- having severe physical diseases such as cardiovascular, lung, liver, kidney, and hematopoietic diseases
- satisfied with the diagnostic criteria for other mental disorders based on DSM-5
- having alcohol or substance abuse/dependence
- having mental retardation(WAIS<70) and/or severe cognitive impairment(MMSE<24)
- having visual and / or hearing problems, unable to complete the relevant test
- electroconvulsive or repetitive transcranial magnetic stimulation(rTMS) therapy in the past 3 months
- currently enrolled or participated in other clinical studies in the past 3 months
- participating in regular exercise training in the past 6 months
- failure to sign or refuse to sign informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Control group
daily rehabilitation interventions
|
including Naikan therapy, Morita therapy, group art therapy, group painting therapy
|
|
Experimental: Interventional group
daily rehabilitation interventions and shen-based Qigong exercise
|
including Naikan therapy, Morita therapy, group art therapy, group painting therapy
a 12-week intervention of shen-based Qigong exercise : exercise 5 days a week, about 30 minutes a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change of the Scale for the Assessment of Negative Symptoms (SANS)
Time Frame: Change from Baseline at 3 months
|
Negative symptoms will be evaluated using the Scale for the Assessment of Negative Symptoms (SANS).
The scale made up for the lack of attention to negative symptoms in previous psychiatric rating scales.
It contains five subscales: affective blunting, alogia, avolition/apathy, anhedonia/asociality, and attention.
A total of 24 items were scored at 6 levels for each item.
|
Change from Baseline at 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change of Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time Frame: Change from Baseline at 3 months
|
RBANS will be used to assess global cognitive function.
RBANS yields scaled scores for 5 cognitive domains and shows a good effect in cognitive assessment of patients with schizophrenia.
|
Change from Baseline at 3 months
|
|
change of event-related potential P300 (ERP P300)
Time Frame: Change from Baseline at 3 months
|
ERP P300 will be used to assess global cognitive function.
ERP P300 is an endogenous cognitive component related to high-level psychological activities such as attention, memory, feeling, learning and reasoning.
It has good stability and can reflect the level of cognitive function from different aspects.
|
Change from Baseline at 3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change of n-back task
Time Frame: Change from Baseline at 3 months
|
Specific cognitive domain--working memory will be assessed by n-back task.
N-back task paradigm is the most classical paradigm in working memory research.
|
Change from Baseline at 3 months
|
|
change of 36-item Short Form Health Survey(SF-36)
Time Frame: Change from Baseline at 3 months
|
36-item Short Form Health Survey(SF-36)will be used to assess the health-related quality of life of patients.
SF-36 is one of the most commonly used standardized measurement tools for quality of life in the world, including eight subscales, a total of 36 items, involving physical and mental health.
|
Change from Baseline at 3 months
|
|
change of Social-Adaptive Functioning Evaluation (SAFE)
Time Frame: Change from Baseline at 3 months
|
Social functions will be assessed using Social-Adaptive Functioning Evaluation (SAFE).
SAFE can evaluate the social adaptation function of patients with mental disorders over 18 years old.
It has a total of 19 items, divided into basic life skills, advanced life skills, social skills and communication skills in four areas; each item 0-4 score, the higher the score, the more serious the damage.
|
Change from Baseline at 3 months
|
|
change of the Scale for the Assessment of Positive Symptoms (SAPS)
Time Frame: Change from Baseline at 3 months
|
Positive symptoms will be evaluated using the Scale for the Assessment of Positive Symptoms (SAPS).
SAPS measures positive symptoms on a 34 item, 6-point scale, a total of 170 points.
Items are listed under hallucinations, delusions, bizarre behavior, and positive formal thought disorder.
|
Change from Baseline at 3 months
|
|
change of heart rate variability (HRV)
Time Frame: Change from Baseline at 3 months
|
Heart rate variability (HRV) will be used as the evaluation index for cardiac function.
HRV is a widely used non-invasive tool for evaluating cardiac autonomic nerve function.
|
Change from Baseline at 3 months
|
|
change of height
Time Frame: Change from Baseline at 3 months
|
Height will be measured using a height ruler, expressed in meters.
|
Change from Baseline at 3 months
|
|
change of weight
Time Frame: Change from Baseline at 3 months
|
Weight will be measured using a weighting scale, expressed in kilograms.
|
Change from Baseline at 3 months
|
|
change of waistline
Time Frame: Change from Baseline at 3 months
|
Waistline will be measured using a flexible rule, expressed in centimeters.
|
Change from Baseline at 3 months
|
|
change of blood pressure
Time Frame: Change from Baseline at 3 months
|
Blood pressure will be measured using a sphygmomanometer, expressed in millimeter of mercury.
|
Change from Baseline at 3 months
|
|
change of gait data
Time Frame: Change from Baseline at 3 months
|
Acquire gait data in a quiet, well-lit room.
Specify the walking area to guide the participants to complete the walking cycle.
|
Change from Baseline at 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Qing Fan, Shanghai Mental Health Center
- Study Chair: Xiaodan Liu, School of Rehabilitation Science, Shanghai University of Traditional Chinese Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 16, 2022
Primary Completion (Anticipated)
June 1, 2023
Study Completion (Anticipated)
June 1, 2023
Study Registration Dates
First Submitted
February 22, 2022
First Submitted That Met QC Criteria
March 26, 2022
First Posted (Actual)
April 5, 2022
Study Record Updates
Last Update Posted (Actual)
October 26, 2022
Last Update Submitted That Met QC Criteria
October 25, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YSF2021-59
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States, India
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Shanghai Zhongze Therapeutics Co., Ltd.Yale UniversityNot yet recruiting
-
Ole Köhler-ForsbergAarhus University HospitalRecruiting
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Recruiting
-
Bradley LegaRecruiting
Clinical Trials on daily rehabilitation interventions
-
Chengdu Sport UniversityNot yet recruitingMyocardial Injury | Long COVID
-
Aveiro UniversityFundação para a Ciência e a TecnologiaCompletedChronic Respiratory DiseasePortugal
-
Aveiro UniversityFundação para a Ciência e a TecnologiaRecruitingAcute Exacerbation of Chronic Obstructive Pulmonary DiseasePortugal
-
National Taiwan University HospitalUnknown
-
Fondazione Salvatore MaugeriAzienda Ospedaliero, Universitaria Pisana; Ataturk Training and Research HospitalCompletedChronic Respiratory InsufficiencyItaly
-
Cumhuriyet UniversityCompletedCIPN - Chemotherapy-Induced Peripheral Neuropathy | Oxaliplatin | Oxaliplatin Induced Peripheral Neuropathy in Cancer PatientsTurkey (Türkiye)
-
University Hospital, Gentofte, CopenhagenUnknownChronic Heart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVDenmark
-
Boston Medical CenterNational Center for Complementary and Integrative Health (NCCIH)Active, not recruiting
-
Ege UniversityThe Scientific and Technological Research Council of TurkeyCompleted
-
International Food Policy Research InstituteFHI 360; Addis Continental Institute of Public HealthCompletedDietary DiversityUnited States